M&A Deal Summary

American Industrial Partners Acquires Aker BioMarine - Feed Ingredients Business

On July 9, 2024, private equity firm American Industrial Partners acquired life science company Aker BioMarine - Feed Ingredients Business from Aker BioMarine ASA

Acquisition Highlights
  • This is American Industrial Partners’ 1st transaction in the Life Science sector.
  • This is American Industrial Partners’ 1st transaction in Norway.

M&A Deal Summary

Date 2024-07-09
Target Aker BioMarine - Feed Ingredients Business
Sector Life Science
Buyer(s) American Industrial Partners
Sellers(s) Aker BioMarine ASA
Deal Type Divestiture

Target

Aker BioMarine - Feed Ingredients Business

Norway
Aker BioMarine's Feed Ingredients Business is an industrial-scale krill harvester and brings a natural, sustainable, and health-promoting source of nutrients into both animal and human nutrition.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

American Industrial Partners

New York, New York, United States

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1989
PE ASSETS 10.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

American Industrial Partners is a private equity firm focused on investments in North American manufacturing or industrial service companies. For platform acquisitions, the Firm seeks businesses with at least $500 million of revenue and the Firm will consider transactions valued up to $2 billion. Operating characteristics of prospective businesses include historical record of strong free cash flows, opportunities to drive value through operating enhancements, and sustainable competitive advantages. American Industrial Partners will consider a variety of transaction types including leveraged buyouts, structured equity investments, bridge financings, senior debt, carve-outs, take privates, turnarounds, and rescue financings. American Industrial Partners was formed in 1989 and is based in New York City.


DEAL STATS #
Overall 50 of 53
Sector (Life Science) 1 of 1
Type (Divestiture) 16 of 19
Country (Norway) 1 of 1
Year (2024) 3 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-07-01 Austin Powder

Cleveland, Ohio, United States

Austin Powder offers manufacturing, distributing, and application of industrial explosives for quarrying, surface mining, underground mining, oil and gas, seismic, and construction markets. The company provides a broad range of highly engineered solutions all of which are developed to advance the safety, reliability, and efficiency of breaking rock. Austin Powder was formed in 1833 and is based in Cleveland, Ohio.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-07-25 AGCO - Grain & Protein Division

Duluth, Georgia, United States

AGCO's Grain & Protein Division designs manufactures, and globally markets grain storage and seed processing equipment and solutions as well as feeding, watering, climate management, and control systems for worldwide protein production, principally poultry, swine, and egg.

Buy $700M

Seller(S) 1

SELLER

Aker BioMarine ASA

Oslo, Norway

Category Company
Sector Life Science
DESCRIPTION

Aker BioMarine is an integrated biotechnology company – uniquely positioned to create value from krill harvesting and processing.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Norway) 1 of 1
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-11-01 Trygg Pharma

Oslo, Norway

Trygg Pharma is a Norwegian-based 50/50 joint venture with Aker BioMarine. TPH is a manufacturer of marine-based omega-3 EPA/DHA concentrates for nutraceutical and pharmaceutical applications. EPAX, TPH’s nutraceutical division, is a long-standing leader in marine-based omega-3 EPA/DHA fatty acid concentrates for nutraceutical manufacturers and marketers, with a focus on the high concentrate segment. Trygg Pharma, TPH’s pharmaceutical division, is completing a Phase III FDA study on an omega-3-based drug candidate for hypertriglyceridemia. Trygg Pharma was founded in 2009 and is based in Oslo, Norway.

Buy -